<DOC>
	<DOC>NCT01248754</DOC>
	<brief_summary>The 18F-FDOPA PET tracer is an amino acid analogue that can be used to visualize high-grade glioma not clearly identified on diagnostic MRI. Use of 18F-FDOPA PET will permit neurosurgeons to achieve a complete resection more frequently.</brief_summary>
	<brief_title>Positron Emission Tomography (PET) With 3,4-dihydroxy-6-18F-fluoro-L-enylalanine (18F-FDOPA) Study</brief_title>
	<detailed_description />
	<mesh_term>Dihydroxyphenylalanine</mesh_term>
	<criteria>Contrastenhancing mass on diagnostic brain CT or MRI strongly suggesting a diagnosis of WHO grade III or IV glioma Karnofsky Performance status (KPS) ≥ 70 Age ≥18 years Subject is able to understand and consent to study Glomerular filtration rate (GFR) ≥ 45 ml/minute Indication for urgent craniotomy to relieve mass effect Only stereotactic biopsy indicated because tumour is located in eloquent brain. The enhancement on the T1 MRI sequence involves or abuts the basal ganglia Previous intracranial malignancy or any invasive malignancy unless free of disease &gt; 5 years Prior cranial irradiation Contraindications to systemic radiation exposure: pregnancy or breast feeding Subject exceeds the weight limit of the PET scanner bed (204.5 kg) Subjects taking medication such as Levodopa for the treatment of Parkinson's Disease Allergies or other contraindication to CT contrast or MRI contrast</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Neurosurgery</keyword>
	<keyword>Neuronavigation</keyword>
	<keyword>Positron emission tomography</keyword>
	<keyword>FDOPA</keyword>
</DOC>